Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • shilez
    Member
    • Jun 2010
    • 10

    #1

    overdispersion and biological replicates

    Hello,

    I really appreciate the work of DESeq and EdgeR for taking the overdispersion into account for biological replicates. However assuming when analyzing tumor samples in a few cancer subgroups, do samples in the same subgroup count as "biological replicates" too? Particularly does the overdispersion model in DESeq statistically sound for a potential more variable samples within a subgroup?
  • Simon Anders
    Senior Member
    • Feb 2010
    • 995

    #2
    Originally posted by shilez View Post
    However assuming when analyzing tumor samples in a few cancer subgroups, do samples in the same subgroup count as "biological replicates" too?
    Of course.

    Particularly does the overdispersion model in DESeq statistically sound for a potential more variable samples within a subgroup?
    Yes. (Please have a look at the development version, as we made quite some changes.)

    This is not to say, however, that you are likely to find much if you compare cancer subgroups and have only a few samples per group. Precisely because the variation is so large you need very many samples to have enough power to find significant differences. Furthermore, pairing samples with normal tissue from the same patient (and using GLMs for the analysis) reduces the variability.

    See also this thread: http://seqanswers.com/forums/archive...p/t-11133.html

    Comment

    • shilez
      Member
      • Jun 2010
      • 10

      #3
      Thanks a lot Simon!
      My sample size is 10/subgroup without the normal tissue sequenced from the same individual.

      My primary goal is gene expression analysis and transcript expression analysis.
      I haven't decided on SNP detection, and fusion gene analysis. Do you think 50bp single read would not be powerful enough to get meaningful results?

      Comment

      • Simon Anders
        Senior Member
        • Feb 2010
        • 995

        #4
        I also realized after posting that the thread I mention talks about SNPs, not gene expression, but the problems are similar.

        50bp single-end is definitely sufficient to get good expression values.

        I don't know that much about cancer transcriptomics, but 10 samples sounds like a quite small number to me, especially without matched normal tissue, unless the expression differences between your sub-types are quite pronounced. Better have a good look at the literature (also look at microarray studies, the power issues should be quite similar) to see what sample sizes gave good results in the past.

        Comment

        Latest Articles

        Collapse

        • SEQadmin2
          Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
          by SEQadmin2



          CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

          Despite this, “CRISPR helped turn genome editing from a specialized technique into
          ...
          07-31-2026, 11:01 AM
        • SEQadmin2
          Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
          by SEQadmin2


          Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

          The systematic characterization of the human proteome has
          ...
          07-20-2026, 11:48 AM
        • SEQadmin2
          Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
          by SEQadmin2



          Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
          ...
          07-09-2026, 11:10 AM

        ad_right_rmr

        Collapse

        News

        Collapse

        Topics Statistics Last Post
        Started by SEQadmin2, Yesterday, 07:41 AM
        0 responses
        12 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 08-03-2026, 10:13 AM
        0 responses
        28 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-31-2026, 02:55 AM
        0 responses
        39 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-24-2026, 12:17 PM
        0 responses
        26 views
        0 reactions
        Last Post SEQadmin2  
        Working...